LimmaTech Biologics

Executive Summary

LimmaTech Biologics AG is a clinical-stage Swiss biopharmaceutical company founded in 2015 and based in Schlieren, dedicated to developing innovative vaccines against antimicrobial-resistant (AMR) pathogens. Leveraging proprietary vaccine technology platforms, the company aims to address the growing global health crisis of untreatable infections. As a private entity, LimmaTech has not disclosed total funding or valuation, but its focus on AMR aligns with significant unmet medical need and potential for regulatory incentives. The company's pipeline targets severe bacterial infections, positioning it as a key player in the antibiotic alternatives space. With increasing global attention on AMR, LimmaTech's vaccine candidates could offer prophylactic solutions where traditional antibiotics are failing, potentially reducing morbidity, mortality, and healthcare costs.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase 2 trial for lead vaccine candidate targeting Shigella or other AMR pathogen70% success
• H2 2026Partnership or licensing deal with larger pharmaceutical company for AMR vaccine platform50% success
• Q3 2026Series B or C funding round to advance pipeline60% success